Filana Therapeutics, Inc.
Research Filana Therapeutics, Inc. (FLNA) on Bullrun: market cap USD 21.74M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerFLNA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 21.74M
- Financial periodQ3 2026
- Net income-USD 10.73M
- Free cash flow-USD 6.13M
Valuation Snapshot
latest market cap is USD 21.74M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 90.97M | -USD 32.83M | n/a | -1.88 | USD 95.50M | n/a | USD 74.40M |
| FY2024 | USD 0 | -USD 24.34M | -USD 117.03M | n/a | -1.46 | USD 128.57M | n/a | USD 145.70M |
| FY2023 | USD 0 | -USD 97.22M | -USD 82.44M | n/a | -2.32 | USD 121.14M | USD 0 | USD 137.47M |
| FY2022 | USD 0 | -USD 76.25M | -USD 80.23M | n/a | -1.9 | USD 201.02M | USD 139.00K | USD 227.54M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-06 | USD 21.74M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 95.65M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 113.76M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 950.75M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.23B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.75B | n/a | n/a | n/a |
About Filana Therapeutics, Inc.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Filana Therapeutics, Inc.'s market cap?
Filana Therapeutics, Inc.'s market capitalization is USD 21.74M.
What does Filana Therapeutics, Inc. do?
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026.